JP2019519479A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519479A5 JP2019519479A5 JP2018555725A JP2018555725A JP2019519479A5 JP 2019519479 A5 JP2019519479 A5 JP 2019519479A5 JP 2018555725 A JP2018555725 A JP 2018555725A JP 2018555725 A JP2018555725 A JP 2018555725A JP 2019519479 A5 JP2019519479 A5 JP 2019519479A5
- Authority
- JP
- Japan
- Prior art keywords
- topical
- veterinary
- composition
- pharmaceutically
- dipeptidyl peptidase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000699 topical effect Effects 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 17
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 6
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims 6
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 230000002207 retinal effect Effects 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 230000004770 neurodegeneration Effects 0.000 claims 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims 5
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 1
- 108010011459 Exenatide Proteins 0.000 claims 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims 1
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 claims 1
- 101500028773 Homo sapiens Glucagon-like peptide 1(7-37) Proteins 0.000 claims 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims 1
- 108010019598 Liraglutide Proteins 0.000 claims 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 claims 1
- 229960001667 alogliptin Drugs 0.000 claims 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 claims 1
- 229950009977 anagliptin Drugs 0.000 claims 1
- LDXYBEHACFJIEL-HNNXBMFYSA-N anagliptin Chemical compound C=1N2N=C(C)C=C2N=CC=1C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N LDXYBEHACFJIEL-HNNXBMFYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 229960001519 exenatide Drugs 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229960002458 gemigliptin Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229960002397 linagliptin Drugs 0.000 claims 1
- 229960002701 liraglutide Drugs 0.000 claims 1
- 229960001093 lixisenatide Drugs 0.000 claims 1
- 108010004367 lixisenatide Proteins 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010062198 microangiopathy Diseases 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960004937 saxagliptin Drugs 0.000 claims 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims 1
- 108010033693 saxagliptin Proteins 0.000 claims 1
- 229960004034 sitagliptin Drugs 0.000 claims 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 229950000034 teneligliptin Drugs 0.000 claims 1
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 claims 1
- -1 trellagliptin Chemical compound 0.000 claims 1
- 229960001254 vildagliptin Drugs 0.000 claims 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382190 | 2016-04-29 | ||
| EP16382190.3 | 2016-04-29 | ||
| PCT/EP2017/060234 WO2017186934A1 (en) | 2016-04-29 | 2017-04-28 | Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519479A JP2019519479A (ja) | 2019-07-11 |
| JP2019519479A5 true JP2019519479A5 (https=) | 2020-06-11 |
| JP7068706B2 JP7068706B2 (ja) | 2022-05-17 |
Family
ID=55953092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555725A Active JP7068706B2 (ja) | 2016-04-29 | 2017-04-28 | 網膜神経変性疾患の眼局所治療のためのジペプチジルペプチダーゼ－４阻害剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11013738B2 (https=) |
| EP (1) | EP3448388B1 (https=) |
| JP (1) | JP7068706B2 (https=) |
| KR (1) | KR102411574B1 (https=) |
| CN (1) | CN109152776B (https=) |
| AU (1) | AU2017256803B2 (https=) |
| BR (1) | BR112018072127A2 (https=) |
| CA (1) | CA3022152C (https=) |
| DK (1) | DK3448388T3 (https=) |
| ES (1) | ES2863701T3 (https=) |
| IL (1) | IL262526B (https=) |
| MX (1) | MX383599B (https=) |
| RU (1) | RU2744878C2 (https=) |
| WO (1) | WO2017186934A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7068706B2 (ja) * | 2016-04-29 | 2022-05-17 | フンダシオ オスピタル ウニベルシタリ バル デブロン－インスティテュート デ レセルカ | 網膜神経変性疾患の眼局所治療のためのジペプチジルペプチダーゼ－４阻害剤 |
| RU2727898C1 (ru) * | 2020-02-25 | 2020-07-24 | Общество с ограниченной ответственностью «Необиотек» | Фармацевтическая композиция на основе действующего вещества, ингибитора дипептидилпептидазы-4, для предупреждения развития и лечения сахарного диабета 2 типа |
| CN111166870A (zh) * | 2020-03-18 | 2020-05-19 | 复旦大学附属眼耳鼻喉科医院 | 艾塞那肽在制备滴眼治疗眼部缺血疾病、改善眼部血液循环的药物中的应用 |
| GB202014740D0 (en) * | 2020-09-18 | 2020-11-04 | Invex Therapeutics Ltd | Method of reducing intraocular pressure |
| WO2026078034A1 (en) | 2024-10-09 | 2026-04-16 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Sitagliptin for use in retinal diseases with neovascularization |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19616486C5 (de) * | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| RU2008116578A (ru) * | 2005-09-30 | 2009-11-10 | Новартис АГ (CH) | Применение ингибиторов dpp-iv для лечения аутоиммунных заболеваний и отторжения трансплантата |
| US7560597B2 (en) * | 2007-03-08 | 2009-07-14 | The University Court Of The University Of Aberdeen | 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents |
| WO2009084024A2 (en) * | 2007-11-02 | 2009-07-09 | Glenmark Generics Limited | A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof |
| US20100330177A1 (en) * | 2008-02-05 | 2010-12-30 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor |
| EP2251028A1 (en) * | 2009-05-12 | 2010-11-17 | Biocompatibles Uk Ltd. | Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor |
| CN101921270A (zh) * | 2009-06-16 | 2010-12-22 | 海南德泽药物研究有限公司 | 一种芒果苷小檗碱盐及其制备方法与用途 |
| TWI469785B (zh) * | 2012-04-25 | 2015-01-21 | Inovobiologic Inc | 用於治療代謝性疾病之膳食纖維組成物 |
| JP6368722B2 (ja) * | 2013-03-01 | 2018-08-01 | フンダシオ オスピタル ウニベルシタリ バル デブロン−インスティテュート デ レセルカ | 網膜神経変性疾患の、特に、初期の糖尿病性網膜症及び神経変性が本質的な役割を果たす他の網膜疾患における局所治療における使用のためのペプチド |
| CA2914791A1 (en) * | 2013-06-14 | 2014-12-18 | Boehringer Ingelheim International Gmbh | Dpp-4 inhibitors for treating diabetes and its complications |
| JP7068706B2 (ja) * | 2016-04-29 | 2022-05-17 | フンダシオ オスピタル ウニベルシタリ バル デブロン－インスティテュート デ レセルカ | 網膜神経変性疾患の眼局所治療のためのジペプチジルペプチダーゼ－４阻害剤 |
-
2017
- 2017-04-28 JP JP2018555725A patent/JP7068706B2/ja active Active
- 2017-04-28 US US16/095,621 patent/US11013738B2/en active Active
- 2017-04-28 KR KR1020187033209A patent/KR102411574B1/ko active Active
- 2017-04-28 AU AU2017256803A patent/AU2017256803B2/en active Active
- 2017-04-28 CA CA3022152A patent/CA3022152C/en active Active
- 2017-04-28 ES ES17722716T patent/ES2863701T3/es active Active
- 2017-04-28 WO PCT/EP2017/060234 patent/WO2017186934A1/en not_active Ceased
- 2017-04-28 EP EP17722716.2A patent/EP3448388B1/en active Active
- 2017-04-28 CN CN201780030017.3A patent/CN109152776B/zh active Active
- 2017-04-28 BR BR112018072127-1A patent/BR112018072127A2/pt not_active Application Discontinuation
- 2017-04-28 DK DK17722716.2T patent/DK3448388T3/da active
- 2017-04-28 RU RU2018140127A patent/RU2744878C2/ru active
- 2017-04-28 MX MX2018013022A patent/MX383599B/es unknown
-
2018
- 2018-10-22 IL IL262526A patent/IL262526B/en unknown
-
2021
- 2021-04-29 US US17/244,889 patent/US11918577B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519479A5 (https=) | ||
| US10905770B2 (en) | Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases | |
| CN102164592A (zh) | 可与核黄素一起使用的增强剂用于在圆锥角膜或其它角膜扩张性疾病的治疗中进行角膜交联的用途以及相应眼用组合物 | |
| RU2018140127A (ru) | Ингибиторы дипептидилпептидазы-4 для местного офтальмологического лечения нейродегенеративных заболеваний сетчатки | |
| BRPI0608152A2 (pt) | formulações para tratamento ocular | |
| US20100203165A1 (en) | Compositions and methods for treatment of disorders or conditions of the eye | |
| EP2646010B1 (en) | Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions | |
| US20110130388A1 (en) | Prophylactic or therapeutic agent for axial myopia | |
| JP2013500977A5 (https=) | ||
| WO2021039748A1 (ja) | ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物 | |
| EP3016654B1 (en) | Tauroursodeoxycholic acid (tudca) for use in the treatment of neurodegenerative disorders | |
| AU2017261303A1 (en) | Ophthalmic compositions | |
| RU2017118405A (ru) | Новое лечение роговицы с применением ламинина | |
| AR062395A1 (es) | Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares | |
| RU2017112930A (ru) | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза | |
| JP2020536121A5 (https=) | ||
| JP2017525758A5 (https=) | ||
| JP2008540528A5 (https=) | ||
| CN114423461A (zh) | 组合 | |
| CN104703606B (zh) | 1-金刚烷乙氧基-3-吗啉基-2-丙醇或其药学上可接受的盐在药物组合物中作为视神经网膜保护物使用 | |
| Hauser et al. | Efficacy of sublingual apomorphine (APL-130277) for the treatment of “off” episodes in patients with Parkinson's disease | |
| RU2559580C1 (ru) | Препарат для лечения синдрома "сухого глаза" | |
| WO2012066994A1 (ja) | 神経保護作用を持つ薬剤配合 | |
| TW201318629A (zh) | 以組合透明質酸及黃素腺嘌呤二核苷酸為特徵的角膜上皮細胞死亡抑制劑 | |
| Karakashian et al. | Niacin-induced cystoid macular edema |